DOI:
10.1055/s-00043364
Pharmaceutical Fronts
LinksClose Window
References
Dömötör O, Pelivan K, Borics A, Keppler BK, Kowol CR, Enyedy ÉA.
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
J Pharm Biomed Anal 2018;
154: 321-331
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.